
## Ira S Winer

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/505664/publications.pdf Version: 2024-02-01



IDA S WINED

| #  | Article  | IF   | CITATIONS |
|----|--|------|-----------|
| 1  | Effective expression of small interfering RNA in human cells. Nature Biotechnology, 2002, 20, 505-508.   | 17.5 | 789       |
| 2  | ITF-2, a downstream target of the Wnt/TCF pathway, is activated in human cancers with $\hat{l}^2$ -catenin defects and promotes neoplastic transformation. Cancer Cell, 2002, 1, 145-155.  | 16.8 | 148       |
| 3  | Berzosertib plus gemcitabine versus gemcitabine alone in platinum-resistant high-grade serous<br>ovarian cancer: a multicentre, open-label, randomised, phase 2 trial. Lancet Oncology, The, 2020, 21,<br>957-968.   | 10.7 | 140       |
| 4  | F3-Targeted Cisplatin-Hydrogel Nanoparticles as an Effective Therapeutic That Targets Both Murine and<br>Human Ovarian Tumor Endothelial Cells <i>In vivo</i> . Cancer Research, 2010, 70, 8674-8683.  | 0.9  | 90        |
| 5  | Vulvar/Vaginal Melanoma. International Journal of Gynecological Cancer, 2013, 23, 1118-1126.   | 2.5  | 53        |
| 6  | Lysine Residues Lys-19 and Lys-49 of β-Catenin Regulate Its Levels and Function in T Cell Factor<br>Transcriptional Activation and Neoplastic Transformation. Journal of Biological Chemistry, 2006, 281,<br>26181-26187.  | 3.4  | 47        |
| 7  | The prognostic significance of histologic type in early stage cervical cancer – A multi-institutional study. Cynecologic Oncology, 2015, 137, 474-478.   | 1.4  | 41        |
| 8  | Miniaturized phased-array ultrasound and photoacoustic endoscopic imaging system. Photoacoustics, 2019, 15, 100139.  | 7.8  | 34        |
| 9  | Drosophila split ends Homologue SHARP Functions as a Positive Regulator of Wnt/β-Catenin/T-Cell<br>Factor Signaling in Neoplastic Transformation. Cancer Research, 2007, 67, 482-491.  | 0.9  | 32        |
| 10 | Clinical and Pathologic Characteristics of Serous Carcinoma Confined to the Endometrium.<br>International Journal of Gynecological Pathology, 2013, 32, 181-187.   | 1.4  | 30        |
| 11 | Prognostic value of changes in neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio<br>(PLR) and lymphocyte-to-monocyte ratio (LMR) for patients with cervical cancer undergoing definitive<br>chemoradiotherapy (dCRT). Clinica Chimica Acta, 2020, 510, 711-716. | 1.1  | 30        |
| 12 | Management of squamous cell vulvar cancer: A review. Journal of Obstetrics and Gynaecology<br>Research, 2014, 40, 1217-1225.   | 1.3  | 29        |
| 13 | Significance of Lymphovascular Space Invasion in Uterine Serous Carcinoma. International Journal of<br>Gynecological Pathology, 2015, 34, 47-56.   | 1.4  | 29        |
| 14 | Comparative Analysis of Differentially Expressed miRNAs and their Downstream mRNAs in Ovarian<br>Cancer and its Associated Endometriosis. Journal of Cancer Science & Therapy, 2015, 07, 258-265.  | 1.7  | 28        |
| 15 | Tumor-associated macrophages derived from cancer stem cells. Acta Histochemica, 2020, 122, 151628.   | 1.8  | 18        |
| 16 | Chemotherapy of vulvar cancer: a review. Wiener Klinische Wochenschrift, 2013, 125, 119-128.   | 1.9  | 15        |
| 17 | Primary debulking surgery and neoadjuvant chemotherapy in the treatment of advanced epithelial ovarian carcinoma. Cancer and Metastasis Reviews, 2015, 34, 5-10.   | 5.9  | 12        |
| 18 | Disparities in adjuvant treatment of high-grade endometrial cancer in the Medicare population.<br>American Journal of Obstetrics and Gynecology, 2022, 226, 541.e1-541.e13.  | 1.3  | 12        |

IRA S WINER

| #  | Article   | IF  | CITATIONS |
|----|---|-----|-----------|
| 19 | Molecular profiles of endometrial cancer tumors among Black patients. Gynecologic Oncology, 2022,<br>166, 108-116.  | 1.4 | 11        |
| 20 | Serum folate receptor α (sFR) in ovarian cancer diagnosis and surveillance. Cancer Medicine, 2019, 8,<br>920-927.   | 2.8 | 9         |
| 21 | Hysteroscopic Morcellation in Endometrial Cancer Diagnosis: Increased Risk?. Journal of Minimally<br>Invasive Gynecology, 2021, 28, 1625-1632.  | 0.6 | 9         |
| 22 | Bevacizumab for the Treatment of Non-Resectable Pseudomyxoma peritonei Associated with Mucinous<br>Ovarian Tumor of Low Malignant Potential – A Comparison of Two Cases. Case Reports in Oncology,<br>2010, 3, 1-8.           | 0.7 | 7         |
| 23 | Merkel cell carcinoma in a patient with noninvasive vulvar Paget's disease. American Journal of<br>Obstetrics and Gynecology, 2012, 207, e9-e11.  | 1.3 | 7         |
| 24 | Tubal Ligation and Risk of Endometrial Cancer. International Journal of Gynecological Cancer, 2016, 26, 464-471.  | 2.5 | 7         |
| 25 | Dual-Illumination Ultrasound/ Photoacoustic System for Cervical Cancer Imaging. IEEE Photonics<br>Journal, 2021, 13, 1-10.  | 2.0 | 7         |
| 26 | The Landscape of Glycogen Synthase Kinase-3 Beta Genomic Alterations in Cancer. Molecular Cancer<br>Therapeutics, 2021, 20, 183-190.  | 4.1 | 6         |
| 27 | ONC201 induces the unfolded protein response (UPR) in high―and lowâ€grade ovarian carcinoma cell<br>lines and leads to cell death regardless of platinum sensitivity. Cancer Medicine, 2021, 10, 3373-3387.                   | 2.8 | 6         |
| 28 | A case of progressive mucinous ovarian cancer of low malignant potential responsive to biologic therapy with Bevacizumab. Gynecologic Oncology, 2010, 116, 578-579.   | 1.4 | 5         |
| 29 | Dual-Illumination Ultrasound/Photoacoustic Endoscopic System. , 2020, , .   |     | 4         |
| 30 | Recurrent Omental Hemangiopericytoma: A Therapeutic Challenge. Case Reports in Obstetrics and<br>Gynecology, 2016, 2016, 1-4.   | 0.3 | 2         |
| 31 | Involvement and comfort of gynecologic oncologists in the treatment of pediatric, adolescent, and young adult patients with gynecologic malignancies. International Journal of Gynecology and Obstetrics, 2017, 138, 177-182. | 2.3 | 2         |
| 32 | Incidence and Survival of Multiple Primary Cancers in US Women With a Gynecologic Cancer.<br>Frontiers in Oncology, 2022, 12, 842441.   | 2.8 | 2         |
| 33 | Abstract CT180: Safety and efficacy of vibostolimab (vibo) plus pembrolizumab (pembro) and<br>coformulation of vibo/pembro in ovarian cancer naive to PD-1/PD-L1 inhibitors. Cancer Research, 2022,<br>82, CT180-CT180.       | 0.9 | 0         |